Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 2Stomatitis 2Squamous Cell Carcinoma of Head and Neck 2Mouth Neoplasms 2Leukemia, Myeloid, Acute 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Tonsillar Neoplasms 1Tongue Neoplasms 1Rectal Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Malignant Solid Neoplasm 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Maxillary Sinus Neoplasms 1Lymphoma, B-Cell 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Carcinoma 1

Interventions

Specimen Handling 4Docetaxel 3trastuzumab biosimilar HLX02 2pertuzumab 2Trastuzumab 2Taxes 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Biopsy 22C4 antibody 2pembrolizumab 1fisetin 1abemaciclib 1Steroids 1Standard of Care 1Rifaximin 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Minoxidil 1Immunoglobulin G 1Imlunestrant 1Hormones 1High-Energy Shock Waves 1Goserelin 1Genetic Testing 1Disulfides 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage I Breast Cancer AJCC v8 × Practice Guidelines as Topic × Clear all
NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Mayo Clinic

Phase 2 Terminated
20 enrolled 13 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡